ARAMIS
ARAMIS showed that darolutamide, an androgen receptor blocker that barely enters the brain, delayed metastases and lengthened life in men whose prostate cancer was rising on hormone therapy but not yet visible on scans, with side effects close to placebo.
Overview
ARAMIS randomised 1509 men with non-metastatic castration-resistant prostate cancer and a PSA doubling time of ten months or less two to one to darolutamide or placebo alongside androgen deprivation. The primary endpoint was metastasis-free survival.
Darolutamide lengthened metastasis-free survival substantially and improved overall survival in the final analysis, with rates of fatigue, falls, fractures, seizures and cognitive effects that were close to placebo, a tolerability profile attributed to its low penetration of the blood-brain barrier. It was approved in the United States in July 2019 and is often preferred among the three androgen receptor inhibitors for this setting in older men.
Similar pages
not linked directly; found by shared links- TrialARANOTE
Shares Darolutamide, Bayer, Prostate cancer and the tag subtype-trials.
- TrialPROSPER
Shares Non-metastatic castration-resistant prostate cancer, Prostate cancer and the tag subtype-trials.
- TrialGRID
Shares Bayer and the tag subtype-trials.
- TrialREGOBONE
Shares Bayer and the tag subtype-trials.
- TrialENZAMET
Shares Prostate cancer and the tag subtype-trials.
- TrialA Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have Hi
Shares Darolutamide, Bayer, Prostate cancer.
- TrialA Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer
Shares Darolutamide, Bayer, Prostate cancer.
- TrialStudy to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
Shares Darolutamide, Bayer.